iSpecimen (ISPC) AGM 2026 summary

Opening remarks and agenda

• Meeting convened online at 10:00 a.m. ET; Aug. 12, 2026 record-date holders had one vote per share, with 2,518,590 shares outstanding.

• Quorum established with 1,287,547 shares represented, approximately 51.12% of outstanding shares, above the 34% threshold.

• Agenda comprised five proposals covering securities issuance, a reverse stock split, future financing issuances, an asset acquisition and adjournment.

Board and executive committee updates

• Board unanimously recommended voting in favor of proposals 1 through 5.

Shareholder proposals

• Proposal 1 sought Nasdaq approval for shares and warrant-related issuances under the May 18, 2026 securities purchase agreement, potentially exceeding 19.9% of pre-transaction shares at below Nasdaq’s minimum price.

• Proposal 2 sought authorization for a 1-for-10 to 1-for-100 reverse split, with the Board choosing the exact ratio; voting was extended to Oct. 30, 2026.

• Proposal 3 sought approval for securities issuances in future financings during the 12 months after approval, including conversion or exercise prices reflecting an 80% discount from the applicable lowest VWAP.

• Proposal 4 sought approval of the Sept. 4, 2026 asset purchase agreement with Foldlab AI Ltd., including common shares as partial consideration; closing was conditioned on stockholder approval.

• Proposal 5 authorized adjournment to solicit additional proxies; the authority was used to extend voting on proposal 2.